Efficacy & safety of sodium-glucose cotransporter-2 inhibitors in polycystic ovary syndrome: A meta-analysis with trial sequential analysis
Abstract
Background & objectives Polycystic ovary syndrome (PCOS) is a common endocrinopathy characterised by menstrual irregularities, hirsutism, acne, obesity, infertility, and other features adversely affecting the quality of life of women of childbearing age. Besides lifestyle modifications, limited pharmacological treatments have been used to manage the symptoms of PCOS. This meta-analysis was conducted to evaluate a novel pharmacological approach, sodium glucose cotransporter-2 inhibitors (SGLT2i), in PCOS. Methods Electronic databases were searched systematically for literature published before November 2024. Randomised controlled trials (RCTs) evaluating SGLT2i alone or in combination in women diagnosed with PCOS, based on the Rotterdam criteria, were included in the meta-analysis. Preclinical studies, and non-randomised trials, were excluded. Quality of studies was assessed using RoB 2.0. Meta-analysis was performed for change in anthropometry, reproductive hormone levels, glycaemic and cardiometabolic indices. Adverse events (AEs) were also compared between the SGLT2i and control groups, using RevMan 5.4.1. Mean difference using the inverse-variance method and 95% confidence interval was used as a measure of effect size of continuous variables, while odds ratio (OR)using the Mantel-Haenszel method (M-H) with 95% confidence interval was calculated to analyse dichotomous variables. P value less than 0.5 was the cut-off for significance. Trial sequential analysis (TSA) was…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 205 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.